Express Scripts (ESRX) Deal is Huge Win for VIVUS (VVUS); Qsymia Reimbursement Will Improve
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- Wall St ends higher on cool inflation data, strong earnings
- U.S. headline producer inflation posts first one-month decrease since August 2025
- PayPal rallies 20% on report Stripe, Advent made $53 billion bid
- Oil prices make small gain on smaller US inventory draw
- ASML capacity upgrade soothes AI chip bottleneck fears
JPMorgan Confident Orexigen's (OREX) Will Receive FDA Approval; Comments on Meeting
December 21, 2012 11:56 AM ESTOrexigen Therapeutics (Nasdaq: OREX) shares are up on the session following a little pressure earlier in the week on its Contrave NDA resubmission.
JPMorgan is out with comments following Orexigen's analyst day this week. The firm remains confident on approvability of Contrave and that any good news from Arena Pharmaceuticals (Nasdaq: ARNA) and VIVUS, Inc. (Nasdaq:... More
Arena (ARNA), Orexigen (OREX) on Watch as Major PBM Adds Qsymia to Formularies List (VVUS)
December 20, 2012 6:34 AM ESTVIVUS, Inc. (NASDAQ: VVUS) peers Arena Pharmaceutials (Nasdaq: ARNA) and Orexigen (Nasdaq: OREX) are ticking higher following reports that major Pharmacy Benefit Manager (PBM) Express Scripts (Nasdaq:... More
VIVUS (VVUS) Says Qsymia Now Covered by Express Scripts' (ESRX)
December 20, 2012 6:31 AM ESTVIVUS, Inc. (NASDAQ: VVUS) today announced that Express Scripts (Nasdaq: ESRX), among the country's largest Pharmacy Benefit Managers (PBMs), has added Qsymia to its national pharmacy formularies, allowing for coverage where available by benefit design of the first... More
